BR112014014604A2 - processo para a preparação de um composto, e, composto isolado e purificado - Google Patents
processo para a preparação de um composto, e, composto isolado e purificadoInfo
- Publication number
- BR112014014604A2 BR112014014604A2 BR112014014604A BR112014014604A BR112014014604A2 BR 112014014604 A2 BR112014014604 A2 BR 112014014604A2 BR 112014014604 A BR112014014604 A BR 112014014604A BR 112014014604 A BR112014014604 A BR 112014014604A BR 112014014604 A2 BR112014014604 A2 BR 112014014604A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparation
- isolated
- purified
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- WPYJKGWLDJECQD-UHFFFAOYSA-N quinoline-2-carbaldehyde Chemical compound C1=CC=CC2=NC(C=O)=CC=C21 WPYJKGWLDJECQD-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
1 / 1 resumo âprocesso para a preparaãão de um composto, e, composto isolado e purificadoâ a invenã§ã£o se refere a um processo para a preparaã§ã£o de um composto de fã³rmula (i) n f ch 3 n 1 co r 2 (i) 1 em que r ã© alquila c -c ou benzila por reaã§ã£o de um composto de fã³rmula 1 6 (ii) f ch 3 n 1 co r 2 (ii) 1 em que r ã© como definido para a fã³rmula (i) com 2-quinolina carboxaldeãdo. o processo ã© adequado para o uso em escala industrial.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1121557.1 | 2011-12-15 | ||
| GB201121557A GB201121557D0 (en) | 2011-12-15 | 2011-12-15 | Process |
| PCT/GB2012/000903 WO2013088108A1 (en) | 2011-12-15 | 2012-12-14 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014014604A2 true BR112014014604A2 (pt) | 2017-06-13 |
| BR112014014604B1 BR112014014604B1 (pt) | 2021-01-12 |
Family
ID=45560499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014014604-7A BR112014014604B1 (pt) | 2011-12-15 | 2012-12-14 | processo para a preparação de um composto, e, composto isolado e purificado |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9102658B2 (pt) |
| EP (1) | EP2791129B1 (pt) |
| JP (2) | JP6300277B2 (pt) |
| KR (1) | KR102018929B1 (pt) |
| CN (1) | CN104114548B (pt) |
| AU (1) | AU2012351341B2 (pt) |
| BR (1) | BR112014014604B1 (pt) |
| CA (1) | CA2859281C (pt) |
| CY (1) | CY1117087T1 (pt) |
| DK (1) | DK2791129T3 (pt) |
| EA (1) | EA026617B1 (pt) |
| ES (1) | ES2557762T3 (pt) |
| GB (1) | GB201121557D0 (pt) |
| HK (1) | HK1197671A1 (pt) |
| HR (1) | HRP20151422T1 (pt) |
| HU (1) | HUE028257T2 (pt) |
| IL (1) | IL233132A (pt) |
| ME (1) | ME02348B (pt) |
| MX (1) | MX342273B (pt) |
| PL (1) | PL2791129T3 (pt) |
| PT (1) | PT2791129E (pt) |
| RS (1) | RS54523B1 (pt) |
| SG (1) | SG11201402798RA (pt) |
| SI (1) | SI2791129T1 (pt) |
| SM (1) | SMT201500327B (pt) |
| UA (1) | UA111868C2 (pt) |
| WO (1) | WO2013088108A1 (pt) |
| ZA (1) | ZA201404246B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| GB201322273D0 (en) * | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| GB201407820D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407807D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| US20220184060A1 (en) | 2018-12-27 | 2022-06-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical composition comprising spherical agglomerates of timapiprant |
| CN111978245A (zh) * | 2020-09-15 | 2020-11-24 | 上海毕得医药科技有限公司 | 一种3-氟-2-异丁基吡啶的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006109108A (ru) | 2003-10-14 | 2007-11-20 | Оксаген Лимитед (GB) | Соединения, обладающие активностью антагонистов crth2 рецепторов |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| US7188489B2 (en) | 2005-04-12 | 2007-03-13 | Martello Russell A | Portable air conditioner |
| GB0605743D0 (en) * | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
| KR20090042808A (ko) | 2006-07-22 | 2009-04-30 | 옥사겐 리미티드 | 씨알티에이치2 길항제 활성을 갖는 화합물 |
| US20110124683A1 (en) | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| EP2250161B1 (en) | 2008-01-18 | 2013-10-16 | Atopix Therapeutics Limited | Compounds having crth2 antagonist activity |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| WO2009093026A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| EP2240444A1 (en) | 2008-01-22 | 2010-10-20 | Oxagen Limited | Compounds having crth2 antagonist activity |
| US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| BR112014014558A8 (pt) | 2011-12-16 | 2017-07-04 | Atopix Therapeutics Ltd | composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica |
-
2011
- 2011-12-15 GB GB201121557A patent/GB201121557D0/en not_active Ceased
-
2012
- 2012-12-14 SG SG11201402798RA patent/SG11201402798RA/en unknown
- 2012-12-14 RS RS20150871A patent/RS54523B1/en unknown
- 2012-12-14 AU AU2012351341A patent/AU2012351341B2/en not_active Ceased
- 2012-12-14 EP EP12805725.4A patent/EP2791129B1/en active Active
- 2012-12-14 PT PT128057254T patent/PT2791129E/pt unknown
- 2012-12-14 HU HUE12805725A patent/HUE028257T2/en unknown
- 2012-12-14 US US14/364,509 patent/US9102658B2/en not_active Expired - Fee Related
- 2012-12-14 UA UAA201406835A patent/UA111868C2/uk unknown
- 2012-12-14 ES ES12805725.4T patent/ES2557762T3/es active Active
- 2012-12-14 ME MEP-2015-218A patent/ME02348B/me unknown
- 2012-12-14 MX MX2014007129A patent/MX342273B/es active IP Right Grant
- 2012-12-14 BR BR112014014604-7A patent/BR112014014604B1/pt not_active IP Right Cessation
- 2012-12-14 EA EA201490998A patent/EA026617B1/ru unknown
- 2012-12-14 KR KR1020147017740A patent/KR102018929B1/ko active IP Right Grant
- 2012-12-14 CA CA2859281A patent/CA2859281C/en active Active
- 2012-12-14 DK DK12805725.4T patent/DK2791129T3/en active
- 2012-12-14 SI SI201230408T patent/SI2791129T1/sl unknown
- 2012-12-14 WO PCT/GB2012/000903 patent/WO2013088108A1/en active Application Filing
- 2012-12-14 JP JP2014546621A patent/JP6300277B2/ja not_active Expired - Fee Related
- 2012-12-14 CN CN201280066207.8A patent/CN104114548B/zh not_active Expired - Fee Related
- 2012-12-14 PL PL12805725T patent/PL2791129T3/pl unknown
-
2014
- 2014-06-09 ZA ZA2014/04246A patent/ZA201404246B/en unknown
- 2014-06-15 IL IL233132A patent/IL233132A/en active IP Right Grant
- 2014-10-24 HK HK14110689.9A patent/HK1197671A1/zh not_active IP Right Cessation
-
2015
- 2015-12-23 SM SM201500327T patent/SMT201500327B/it unknown
- 2015-12-23 CY CY20151101189T patent/CY1117087T1/el unknown
- 2015-12-28 HR HRP20151422TT patent/HRP20151422T1/hr unknown
-
2017
- 2017-07-28 JP JP2017146700A patent/JP2018008985A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014014604A2 (pt) | processo para a preparação de um composto, e, composto isolado e purificado | |
| BR112012007085B8 (pt) | processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila | |
| MA35664B1 (fr) | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one | |
| EA201591503A1 (ru) | Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина | |
| AU2011232516A8 (en) | Chemical compounds | |
| CR20120334A (es) | Derivados de imidazopiridina como inhibidores de jak | |
| MX350892B (es) | Síntesis de compuesto antiviral. | |
| BR112012010186A2 (pt) | derivados de heteroarila contendo n como inibidores de quinase jak3. | |
| AU2012213775A8 (en) | 7-azaindole derivatives | |
| BR112013020513A2 (pt) | adoçante stevia altamente solúvel | |
| AU2012334173A8 (en) | [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 | |
| BR112015007295A2 (pt) | processo para a preparação de compostos; compostos; e uso dos mesmos | |
| BR112013031405A2 (pt) | piridopirazinas substituídas como novos inibidores de syk | |
| BR112013001335A2 (pt) | processo de preparo de derivados de amino-benzoil-benzofurano | |
| AU2014230812A8 (en) | Process for making benzoxazepin compounds | |
| BR112012032251A2 (pt) | processo para a preparação de derivados da 2, 2-difluoroetilamina pela alquilação com 2,2 difluoroetil-1-haloetanos | |
| BRPI0821102A2 (pt) | Preparação de derivados de di-hidropirrol como intermediários | |
| ECSP099070A (es) | Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios | |
| BR112015006370A2 (pt) | meios e métodos para tratamento de tumores sólidos | |
| BR112014009390A2 (pt) | corantes ácidos de trisazóicos | |
| BR112015015798A2 (pt) | método para a preparação de um composto | |
| BR112015015229A2 (pt) | processo para a preparação de um composto da fórmula, composto, e, invenção | |
| MX2013003498A (es) | Derivados de cromeno. | |
| BR112015016647A2 (pt) | processo para a preparação de um derivado de fluorlactona | |
| BR112013024361A2 (pt) | novos compostos de azaspirodecanona como inibidores de hsl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2012, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2753 DE 10-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |